Andrew Cooper
Stock Analyst at Raymond James
(2.43)
# 1,376
Out of 5,050 analysts
150
Total ratings
43.61%
Success rate
-0.04%
Average return
Main Sectors:
Stocks Rated by Andrew Cooper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITGR Integer Holdings | Reiterates: Outperform | $143 → $95 | $68.26 | +39.17% | 4 | Oct 24, 2025 | |
| HOLX Hologic | Downgrades: Market Perform | n/a | $74.10 | - | 13 | Oct 22, 2025 | |
| AVTR Avantor | Maintains: Outperform | $14 → $16 | $11.55 | +38.53% | 16 | Oct 16, 2025 | |
| HAE Haemonetics | Downgrades: Outperform | $105 → $78 | $68.36 | +14.10% | 10 | Aug 11, 2025 | |
| AZTA Azenta | Upgrades: Outperform | $35 | $29.37 | +19.17% | 2 | Aug 6, 2025 | |
| GH Guardant Health | Maintains: Outperform | $59 → $61 | $96.72 | -36.93% | 4 | Jul 31, 2025 | |
| RVTY Revvity | Reiterates: Outperform | $120 → $115 | $90.78 | +26.68% | 9 | Jul 29, 2025 | |
| TMO Thermo Fisher Scientific | Reiterates: Outperform | $525 → $535 | $572.41 | -6.54% | 7 | Jul 24, 2025 | |
| MYGN Myriad Genetics | Reiterates: Outperform | $19 → $10 | $6.30 | +58.73% | 5 | May 7, 2025 | |
| FLGT Fulgent Genetics | Reiterates: Outperform | $24 → $25 | $26.36 | -5.16% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $226.11 | - | 1 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $209.94 | - | 8 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $66.18 | - | 8 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $15.62 | - | 16 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $68 → $85 | $199.57 | -57.41% | 5 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $100 → $76 | $20.35 | +273.46% | 12 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $4.62 | - | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.08 | - | 14 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $41.70 | - | 8 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.40 | - | 5 | Sep 22, 2021 |
Integer Holdings
Oct 24, 2025
Reiterates: Outperform
Price Target: $143 → $95
Current: $68.26
Upside: +39.17%
Hologic
Oct 22, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $74.10
Upside: -
Avantor
Oct 16, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $11.55
Upside: +38.53%
Haemonetics
Aug 11, 2025
Downgrades: Outperform
Price Target: $105 → $78
Current: $68.36
Upside: +14.10%
Azenta
Aug 6, 2025
Upgrades: Outperform
Price Target: $35
Current: $29.37
Upside: +19.17%
Guardant Health
Jul 31, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $96.72
Upside: -36.93%
Revvity
Jul 29, 2025
Reiterates: Outperform
Price Target: $120 → $115
Current: $90.78
Upside: +26.68%
Thermo Fisher Scientific
Jul 24, 2025
Reiterates: Outperform
Price Target: $525 → $535
Current: $572.41
Upside: -6.54%
Myriad Genetics
May 7, 2025
Reiterates: Outperform
Price Target: $19 → $10
Current: $6.30
Upside: +58.73%
Fulgent Genetics
May 5, 2025
Reiterates: Outperform
Price Target: $24 → $25
Current: $26.36
Upside: -5.16%
Mar 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $226.11
Upside: -
Feb 3, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $209.94
Upside: -
Sep 26, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $66.18
Upside: -
May 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $15.62
Upside: -
Feb 20, 2024
Downgrades: Outperform
Price Target: $68 → $85
Current: $199.57
Upside: -57.41%
Feb 14, 2024
Downgrades: Outperform
Price Target: $100 → $76
Current: $20.35
Upside: +273.46%
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $4.62
Upside: -
May 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $10.08
Upside: -
Jan 18, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $41.70
Upside: -
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $2.40
Upside: -